Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter involved in the embryonic neural development and adult neurogenesis. But the effects of 5-HT on stem cells are not fully known. In this study, the effects and underlying signal pathways of 5- HT on proliferation and neural differentiation of mouse embryonic stem (ES) cells, neural progenitor (NP) cell line C 17.2 and embryonic neural stem (NS) cells were explored. Molecular analysis, immunostaining and western blotting revealed that NP/NB cells expressed the rate-limiting enzyme tryptophan hydroxylase (TPH) and produced endogenous 5-HT. While mouse ES cells showed no expression of TPH. Quantitative PCR demonstrated that ES cells and NPINS cells expressed majority of 5-HT receptor sUbtypes. In serum free propagation culture, WST1, BrdU incorporation and neural colony forming cell assay demonstrated that 5-HT enhanced proliferation of ES cells and NPINS cells in a dose-dependent manner. Tryptophan hydroxylase (TPH) inhibitor para-chlorophenylalanine (PCPA) which can inhibit biosynthesis of endogenous 5-HT decreased viability of mouse NP/NS cells. Mouse ES cells derived embryoid bodies (EB) and NS/NP cells were subjected to neural induction in serum-free medium with and without 5-HT or PCPA. On day 8 of EB cultures, immunofluorescence staining displayed a less percentage of SSEA-1+ cells derived from cultures supplemented with 5-HT. Nestin positivity are comparable. Quantitative PCR analysis suggested that supplement of 5-HT in EB culture inhibit neural differentiation of ES cells and induce mesodermal commitment. On day 21 of ES cells neural induction, compared to cultures without 5-HT treatment, a significantly less number of ß-tubulin III+ neurons, GEAP+ astrocytes and GaIC+ oligodendrocytes were noted in 5-HT -supplemented cultures. For NS/NP cells, the inhibitory effects of 5-HT on neuronal and oligodendrocytic commitment were also observed. And the application of PCPA exerted a promoting effect on neural differentiation of NS cells. Manipulating 5-HT level can affect the expression level of key genes which involved in 5-HT metabolism. ES and NS/NP cells treated with 5-HT showed decreased production of endogenous reactive oxygen species (ROS). 5-HT demonstrated a significant anti-apoptotic effect on NP cells and this antiapoptotic effect may be mediated by up-regulated expression of anti-apoptotic gene Bel- 2. Whole genome cDNA microarray analysis and quantitative RT-PCR revealed that notch signal pathway was involved in mediating the biological effects of 5-HT. Western blotting further confirmed that 5-HT treatment up-regulated the protein level of NICD and notch downstream effectors Hes-l and Hes-5. Finally, the therapeutic effects of ES cell-derived neural cells were testified in a mouse model of global ischemia. Two weeks post-transplantation, BrdU labeled ES cell-derived neural cells survived and migrated throughout brain parenchyma. A majority of transplanted cells remained nestin positive. The cognitive functions of cell transplanted groups showed significant recovery compared with untransplanted arms, but no significant difference was observed between transplanted groups treated with and without 5-HT. Taken together, data of this study indicated 5-HT play an important role in neural development and ES cell-derived neural cells might be applicable in the treatment of stroke. / Li, Jin. / "November 2011." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 195-241). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese. / Abstracts in English. / ACKNOWLEDGEMENTS --- p.i / LIST OF PUBLICATIONS --- p.ii / ABSTRACT --- p.iii / ABSTRACT [in Chinese] --- p.v / TABLE OF CONTENT --- p.vi / LISTS OF FLOWCHARTS --- p.xii / LISTS OF FIGURES --- p.xiii / LIST OF TABLES --- p.xvi / LIST OF EQUIPMENTS --- p.xvii / LIST OF ABBREVATIONS --- p.xvii / Chapter Chapter1 --- Introduction --- p.1 / Chapter 1.1 --- Central nervous system disorder --- p.1 / Chapter 1.1.1 --- Stroke --- p.1 / Chapter 1.1.2 --- Spinal cord injuries --- p.4 / Chapter 1.1.3 --- Parkinson's disease --- p.6 / Chapter 1.1.4 --- Amyotrophic Lateral Sclerosis --- p.8 / Chapter 1.2 --- Stem cell therapy --- p.10 / Chapter 1.2.1 --- General considerations in stem cell therapy --- p.11 / Chapter 1.2.2 --- Stem cell therapy for stroke --- p.11 / Chapter 1.2.3 --- Stem cell therapy for spinal cord injury --- p.15 / Chapter 1.2.4 --- Stem cell therapy for Parkinson's disease --- p.16 / Chapter 1.2.5 --- Stem cell therapy for ALS --- p.18 / Chapter 1.3 --- Stem cells --- p.20 / Chapter 1.3.1 --- Embryonic stem cells --- p.21 / Chapter 1.3.1.1 --- Derivation and characterization --- p.21 / Chapter 1.3.1.2 --- Biology of ES cells --- p.21 / Chapter 1.3.1.2.1 --- Pluripotency of ES cells --- p.21 / Chapter 1.3.1.2.2 --- Differentiation of ES cells to multiple lineages --- p.24 / Chapter 1.3.1.2.2.1 --- Ectodermal differentiation --- p.25 / Chapter 1.3.1.2.2.2 --- Mesodermal differentiation --- p.27 / Chapter 1.3.1.2.2.3 --- Endodermal differentiation --- p.28 / Chapter 1.3.2 --- Neural stem cells --- p.30 / Chapter 1.3.2.1 --- Derivation and characterization --- p.30 / Chapter 1.3.2.2 --- Biology of NS cells --- p.32 / Chapter 1.3.3 --- Induced pluripotent stem cells --- p.34 / Chapter 1.3.4 --- Mesenchymal stem cells --- p.35 / Chapter 1.4 --- Serotonin (5-HT) --- p.36 / Chapter 1.4.1 --- Distribution --- p.37 / Chapter 1.4.2 --- Metabolism --- p.37 / Chapter 1.4.3 --- Biological effects of 5-HT --- p.38 / Chapter 1.4.4 --- Serotonin receptor subtypes and receptor signal transduction pathways --- p.40 / Chapter Chapter2 --- Aim --- p.43 / Chapter 2.1 --- Hypothesis and study objectives --- p.43 / Chapter Chapter3 --- Materials and Methods --- p.49 / Chapter 3.1 --- Chemicals and Reagents --- p.49 / Chapter 3.1.1 --- Cell culture --- p.49 / Chapter 3.1.2 --- Serotonin, serotonin receptor subtypes specific agonists/antagonists and drugs that regulate serotonin metabolism --- p.51 / Chapter 3.1.3 --- Cell proliferation assay --- p.52 / Chapter 3.1.4 --- Cell apoptosis assay --- p.52 / Chapter 3.1.5 --- Immunohistochemistry and staining --- p.52 / Chapter 3.1.6 --- Western blotting --- p.55 / Chapter 3.1.7 --- Molecular biology --- p.56 / Chapter 3.1.8 --- Whole genome cDNA micro array --- p.58 / Chapter 3.1.9 --- MAO activity assay --- p.58 / Chapter 3.1.10 --- Endogenous ROS production assay --- p.58 / Chapter 3.2 --- Consumable --- p.58 / Chapter 3.3 --- Cells --- p.60 / Chapter 3.3.1 --- Feeder cell --- p.60 / Chapter 3.3.1.1 --- Mouse embryonic fibroblasts --- p.60 / Chapter 3.3.2 --- ES cells --- p.61 / Chapter 3.3.2.1 --- ES cell D3 --- p.61 / Chapter 3.3.2.2 --- ES cell-E14TG2a --- p.61 / Chapter 3.3.3 --- NS cells --- p.61 / Chapter 3.3.3.1 --- Neural progenitor cells line C172 --- p.61 / Chapter 3.3.3.2 --- Mouse embryonic neural stem cells --- p.61 / Chapter 3.4 --- In-house prepared solutions --- p.62 / Chapter 3.4.1 --- Stock solution ofInsulin, Transferrin, Selentine (ITS) Supplement --- p.63 / Chapter 3.4.2 --- Gelatin solution 01% --- p.62 / Chapter 3.4.3 --- Paraformaldehyde solution 4% (PFA) --- p.62 / Chapter 3.4.4 --- Tritox X-lOO solution 03% --- p.63 / Chapter 3.4.5 --- Popidium iodide solution 1 ug/ml (PI) --- p.63 / Chapter 3.4.6 --- Poly-L-ornithine solution --- p.63 / Chapter 3.4.7 --- Laminin solution --- p.64 / Chapter 3.4.7 --- MEF Maintenance medium --- p.64 / Chapter 3.4.9 --- Cryopreservation Media for MEF and C172 (2X) --- p.64 / Chapter 3.4.10 --- Cryopreservation Media for mouse ES cell (2X) --- p.65 / Chapter 3.4.11 --- Cryopreservation Media for mouse NS cell (2X) --- p.65 / Chapter 3.4.12 --- Serum based maintenance medium for C172 --- p.65 / Chapter 3.4.13 --- Serum free maintenance medium for C172 --- p.66 / Chapter 3.4.14 --- Serum-based propagation medium for ES cells --- p.66 / Chapter 3.4.15 --- Serum-free propagation medium forES cells --- p.67 / Chapter 3.4.16 --- Serum-free induction medium for ES cells --- p.67 / Chapter 3.4.16.1 --- Serum-free induction medium I --- p.67 / Chapter 3.4.16.2 --- Serum-free induction medium II --- p.68 / Chapter 3.4.16.3 --- Serum-free induction medium III --- p.68 / Chapter 3.4.17 --- Tris-HCl (1 M), pH 74 --- p.68 / Chapter 3.4.18 --- Tris-HCl (1 M), pH 87 --- p.69 / Chapter 3.4.19 --- Tris-HCI (1 M), pH 69 --- p.69 / Chapter 3.4.20 --- APS 10% (wt/vol) --- p.69 / Chapter 3.4.21 --- Protease inhibitor (10X) --- p.70 / Chapter 3.4.22 --- RIPA --- p.70 / Chapter 3.4.23 --- Resolving buffer (8X) --- p.70 / Chapter 3.4.24 --- Stacking buffer (4X) --- p.71 / Chapter 3.4.25 --- Protein running buffer (lOX) --- p.71 / Chapter 3.4.26 --- Transfer buffer (10X) --- p.72 / Chapter 3.4.27 --- Transfer buffer (IX) --- p.72 / Chapter 3.4.28 --- Blocking buffer (lOX) --- p.72 / Chapter 3.4.29 --- TBS (10X) --- p.73 / Chapter 3.4.30 --- TBS-T (IX) --- p.73 / Chapter 3.4.31 --- Stacking gel --- p.73 / Chapter 3.4.32 --- Resolving gel --- p.74 / Chapter 3.5 --- Methods --- p.75 / Chapter 3.5.1 --- Cell culture --- p.75 / Chapter 3.5.1.1 --- Preparation of acid washed cover slips --- p.75 / Chapter 3.5.1.2 --- Preparation of gelatinized culture wares --- p.75 / Chapter 3.5.1.3 --- Poly-L-omithine and laminin coating --- p.76 / Chapter 3.5.1.4 --- Thawing cryopreserved cells --- p.76 / Chapter 3.5.1.5 --- Passage of culture --- p.77 / Chapter 3.5.1.5 --- 6 Cell count --- p.78 / Chapter 3.5.1.7 --- Cytospin --- p.78 / Chapter 3.5.1.8 --- Trypan blue dye exclusion test --- p.78 / Chapter 3.5.1.9 --- Cryopreservation --- p.79 / Chapter 3.5.1.10 --- Derivation and culture of mouse embryonic fibroblasts (MEF) --- p.79 / Chapter 3.5.1.11 --- Propagation of ES cells in serum-based/free medium --- p.81 / Chapter 3.5.1.12 --- Neural differentiation ofES cells --- p.83 / Chapter 3.5.1.13 --- Propagation ofNP cell C172 in serum-based or serum-free medium --- p.84 / Chapter 3.5.1.14 --- Neural differentiation ofC172 --- p.85 / Chapter 3.5.1.15 --- Derivation and propagation of embryonic NS cells --- p.85 / Chapter 3.5.1.13 --- Neural differentiation of embryonic NS cells --- p.86 / Chapter 3.5.1.17 --- BrdU labeling of the ES cells derived products --- p.87 / Chapter 3.5.2 --- Cell proliferation assay --- p.87 / Chapter 3.5.2.1 --- Cell morphology --- p.87 / Chapter 3.5.2.2 --- WST-1 assay --- p.88 / Chapter 3.5.2.3 --- BrdU incorporation assay --- p.88 / Chapter 3.5.2.4 --- NCFC assay --- p.89 / Chapter 3.5.3 --- Conventional and quantitative RT-PCR --- p.89 / Chapter 3.5.3.1 --- RNA extraction --- p.89 / Chapter 3.5.3.2 --- RNA quantitation --- p.90 / Chapter 3.5.3.3 --- Reverse Transcription ofthe First Strand complementary DNA --- p.90 / Chapter 3.5.3.4 --- Polymerase chain reaction --- p.91 / Chapter 3.5.3.5 --- RNA Integrity Check --- p.91 / Chapter 3.5.3.6 --- Electrophoresis and visualization of gene products --- p.91 / Chapter 3.5.3.7 --- Real-time quantitative PCR --- p.92 / Chapter 3.5.4 --- Microarray --- p.94 / Chapter 3.5.5 --- Immunofluoresent staining --- p.94 / Chapter 3.5.6 --- Western blot --- p.95 / Chapter 3.5.6.1 --- Harvesting samples --- p.95 / Chapter 3.5.6.2 --- Protein extraction --- p.96 / Chapter 3.5.6.3 --- Protein quantification --- p.96 / Chapter 3.5.6.4 --- SDS-PAGE --- p.97 / Chapter 3.5.6.5 --- Wet transfer of protein to PVDF membrane --- p.97 / Chapter 3.5.6.6 --- Blocking the membrane --- p.97 / Chapter 3.5.6.7 --- Immunoblotting --- p.97 / Chapter 3.5.6.8 --- Signal detection --- p.98 / Chapter 3.5.7 --- Cell apoptosis assay --- p.98 / Chapter 3.5.7.1 --- ANNEXINV-FITC apoptosis detection --- p.98 / Chapter 3.5.7.2 --- TUNEL --- p.99 / Chapter 3.5.8 --- Endogenous ROS assay --- p.100 / Chapter 3.5.9 --- In vivo studies --- p.101 / Chapter 3.5.9.1 --- Induction of cerebral ischemia in mice --- p.101 / Chapter 3.5.9.2 --- Transplantation --- p.101 / Chapter 3.5.9.3 --- Assessment of learning ability and memory --- p.102 / Chapter 3.5.10 --- Histological analysis --- p.103 / Chapter 3.5.10.1 --- Animal sacrifice for brain harvest --- p.103 / Chapter 3.5.10.2 --- Cryosectioning --- p.103 / Chapter 3.5.10.3 --- Haematoxylin and eosin staining --- p.104 / Chapter 3.6 --- Data analysis --- p.104 / Chapter Chapter4 --- Results --- p.113 / Chapter 4.1 --- Expression profile of 5-HT receptors and metablism of endogenous 5-HT --- p.113 / Chapter 4.1.1 --- Expression profiles of 5-HT receptors in stem cells --- p.113 / Chapter 4.1.2 --- Biosynthesis of endogenous 5-HT --- p.115 / Chapter 4.2 --- Effects of 5-HT on proliferation of mouse ES cells and NS cells --- p.115 / Chapter 4.2.1 --- Effects of 5-HT on proliferation ofES cells --- p.115 / Chapter 4.2.2 --- Effects of 5-HT on proliferation ofNP and NS cells --- p.117 / Chapter 4.3 --- Effects of 5-HT on differentiation of mouse ES cells and NS cells --- p.119 / Chapter 4.3.1 --- Neural differentiation ofES cells --- p.119 / Chapter 4.3.2 --- Effects of 5-HT on differentiation ofES cells --- p.119 / Chapter 4.3.3 --- Neural differentiation ofNP and NS cells --- p.120 / Chapter 4.3.4 --- Effects of 5-HT on differentiation ofNP and NS cells --- p.121 / Chapter 4.4 --- 5-HT metabolism in mouse ES cells and NS cells --- p.122 / Chapter 4.4.1 --- Expression of key 5-HT metablic genes in stem cells --- p.122 / Chapter 4.4.2 --- Detection ofROS generation in mouse NS cells --- p.123 / Chapter 4.4.3 --- Effects of 5-HT on expression level of MAO-A, MAO-B and SERT --- p.123 / Chapter 4.5 --- Anti-apoptotic effect of 5-HT on NP and NS cells in neural induction --- p.127 / Chapter 4.6 --- Potential signaling pathways mediated by 5-HT --- p.130 / Chapter 4.7 --- Therapeutic effects of 5-HT treated mouse ES cell-derived cells in a stoke model --- p.130 / Chapter 4.7.1 --- Induction of global ischemia by transient BCCAO --- p.130 / Chapter 4.7.1.1 --- HE staining of post ischemic brain --- p.131 / Chapter 4.7.1.2 --- TUNEL analysis of cell apoptosis at post ischemia day 3 --- p.132 / Chapter 4.7.2 --- Cell labelling --- p.132 / Chapter 4.7.3 --- Cognition monitoring post transplantation --- p.133 / Chapter 4.7.4 --- Survival, migration and differentiation of transplanted neural cells --- p.135 / Chapter Chapter5 --- Discussion --- p.180 / Chapter Chapter6 --- Conclusions --- p.192 / References --- p.195

Ischemic brain injury causes neurodegeneration. In this study, the mechanism of neurodegeneration was investigated by examining the role of sterol regulatory element binding protein-1 (SREBP-1), CCAAT enhancer binding protein&amp / #946 / (C/EBP&amp / #946 / ), glutathione (GSH), malondialdehyde (MDA), glutathione-S-transferase (GST), and superoxide dismutase (SOD). Carotid artery occlusion (CAO) plus hypotension was produced for 10 minutes. Control groups were sham operated. Animals were sacrificed after 24 hours, 1 week, 2 and 4 weeks of reperfusion periods. The expression of C/EBP&amp / #946 / and SREBP-1 in rat brain cortex and cerebellum were examined by western blotting. C/EBP&amp / #946 / expressions significantly increased in both cytosolic (1.19, 1.58 fold) and nuclear (1.73, 1.81 fold) extracts of brain cortex at 24 hours and 1 week CAO groups, respectively. In cerebellum, C/EBP&amp / #946 / expression significantly increased in 1 week, cytosolic (1.63 fold), and nuclear (1.35 fold) extracts. SREBP-1 expression increased significantly in both cytosolic (2.07 fold) and nuclear (1.41 fold) extracts of brain cortex in 1 week. SREBP-1 expression significantly increased in cytosolic (2.15 fold) and nuclear (1.79 fold) extracts of cerebellum in 1 week. There were no significant alterations in SREBP-1 C/EBP&amp / #946 / expressions for 2 and 4 weeks in both cytosolic and nuclear extracts of brain cortex and cerebellum. There were insignificant changes in GSH and GST levels in cortex. However, MDA and SOD levels significantly increased by 43.0 % and 47.3 %, respectively, in 24 hours. Our findings indicate that increase in SREBP-1 and C/EBP&amp / #946 / expressions may be related to oxidative stress during ischemic neurodegenerative processes.

Cerebral ischemia is the principal cause of morbidity and mortality worldwide. In addition to neuronal loss associated with hypoxic-ischemic damage, cerebral ischemia is characterized by a neuromicrovascular injury. Nitrative stress and lipid peroxidation increase in hypoxic-ischemic damages and play an essential role in neuromicrovascular injury leading to cerebral ischemia. We hypothesized that newly described lipid peroxidation products, termed trans-arachidonic acids (TAA), could be implicated in the pathogenesis of hypoxia-ischemia by affecting the cerebral vasomotricity and microvascular integrity. / The effects of TAA on neuromicrovascular tone were tested ex vivo by monitoring the changes in vascular diameter of rat cerebral pial microvessels. Four isomers of TAA, namely 5 E-AA, 8E-AA, IIE-AA and 14 E-AA induced an endothelium-dependent vasorelaxation. Possible mechanisms involved in TAA-induced vasorelaxation were thoroughly investigated. Collectively, data enclosed revealed that TAA induce cerebral vasorelaxation through the interactive activation of BKCa channels with heme oxygenase-2. This interaction leads to generation of carbon monoxide which in turn activates soluble guanylate cyclase and triggers vasorelaxation. / Chronic effects of TAA on microvascular integrity were examined by generating a unilateral hypoxic-ischemic (HI) model of cerebral ischemia on newborn rat pups. Our HI model showed microvascular degeneration as early as 24h post-HI, preceded by an increase in cerebral TAA levels. HI-induced microvascular lesions were dependent on nitric oxide synthase activation and ensued TAA formation. Although the molecular mechanisms leading to TAA-induced microvascular degeneration were, in part uncovered for the retina, the primary site of action of TAA remains unknown. We demonstrated that TAA binds and activates GPR40 receptor, a newly described free fatty acid receptor. Importantly, GPR40 receptor knock-out prevents TAA-induced reduction in cerebral microvascular density and limits HI-induced brain infarct.

Thesis (Ph. D.)--West Virginia University, 2007. / Title from document title page. Document formatted into pages; contains x, 154 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references (p. 135-149).

Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico / ApÃs isquemia cerebral, o Trifosfato de Adenosina (ATP) atinge altas concentraÃÃes no espaÃo extracelular e pode atuar como agente tÃxico, que causa degeneraÃÃo celular e morte, mediada atravÃs de receptores P2X e P2Y. No presente estudo, foram investigados os efeitos do PPADS, um antagonista nÃo-seletivo dos receptores P2, sobre o comportamento e dano neuronal apÃs isquemia induzida por oclusÃo permanente da artÃria cerebral mÃdia por eletrocoagulaÃÃo. Os animais receberam PPADS (0,1, 0,5 e 1,0 nmols/1&#956;L) ou fluÃdo cerebroespinhal artificial (FCE) por injeÃÃo intracerebroventricular 10 min antes da isquemia. Os parÃmetros estudados foram funÃÃo sensÃrio-motora, aquisiÃÃo e retenÃÃo de memÃria, Ãrea de infarto cerebral e atividade da MPO, como marcador para infiltraÃÃo granulocÃtica. ApÃs isquemia, verificou-se atravÃs de avaliaÃÃo neurolÃgica, uma diminuiÃÃo significante do desempenho motor e funÃÃo sensorial dos animais. A percentagem da Ãrea de infarto nos animais falso-operados foi significantemente menor que naqueles submetidos à isquemia (FO: 0,89  0,18%; FO + PPADS 1,0: 1,18  0,1%; ISQ: 9,06  1,2%; ISQ + PPADS 0,5: 2,2  0,32%; ISQ + PPADS 1,0: 1,86  0, 18%). Foi observado ainda um aumento da atividade exploratÃria vertical (n de Rearings) nos animais tratados com PPADS quando comparados aos animais do grupo isquemiado (ISQ: 9,5  1,8; ISQ + PPADS 0,5: 26,9  2,9; ISQ + PPADS 1,0: 20,6  3,7; Kruskall-Wallis, p<0.05). O tratamento com PPADS melhorou de forma significante os dÃficits na memÃria operacional induzidos pela isquemia, avaliado no teste do Labirinto em Y (FO: 73,8  1,9%; ISQ: 56,7  2,9%; ISQ + PPADS 0,5: 76,7  3,2%; ISQ + PPADS 1,0: 72,6  4,0%). Um resultado semelhante foi observado na memÃria aversiva (teste da esquiva passiva) no qual o PPADS melhorou a aquisiÃÃo de memÃria de curta duraÃÃo. Os animais isquemiados demonstraram um aumento nos nÃveis de MPO no estriado (FO: 3,6  0,63; ISQ: 16,24  4,86) e cÃrtex temporal (FO: 6,16  1,23; ISQ: 22,33  4,98), e o tratamento com PPADS (1,0 nmols/1&#956;L) reverteu significantemente esse efeito (ISQ + PPADS â estriado: 6,13  0,65; cÃrtex: 6,28  0,38). Os resultados demonstram o envolvimento dos receptores P2 na fisiopatologia da isquemia cerebral. A inibiÃÃo dos receptores P2 pelo PPADS mostrou um significante efeito neuroprotetor sobre o dano neuronal, comportamento motor e memÃria apÃs isquemia e indicam que este efeito pode estar relacionado pelo menos em parte a uma atividade antiinflamatÃria deste composto.

Submitted by JÚLIO HEBER SILVA (julioheber@yahoo.com.br) on 2018-02-07T12:20:16Z No. of bitstreams: 2 Tese - Fernanda Figueiredo Mendes - 2017.pdf: 3143804 bytes, checksum: f54c570c528aec9a899da580fdc4edd6 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Cláudia Bueno (claudiamoura18@gmail.com) on 2018-02-07T12:54:12Z (GMT) No. of bitstreams: 2 Tese - Fernanda Figueiredo Mendes - 2017.pdf: 3143804 bytes, checksum: f54c570c528aec9a899da580fdc4edd6 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-02-07T12:54:12Z (GMT). No. of bitstreams: 2 Tese - Fernanda Figueiredo Mendes - 2017.pdf: 3143804 bytes, checksum: f54c570c528aec9a899da580fdc4edd6 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2017-03-17 / Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEG / The aim was to determine the effect of ethanolic extract of pequi mesocarp on induced brain damage and ERK1/2 and AMPKα active forms in rats subjected to a hypercaloric diet. 48 rats were sorted into two groups of 24 according to the diet used, hypercaloric or commercial, provided daily for 60 days. The animals were separated into two subgroups of 12, treated or not with the extract, given daily for 30 days after diet start. Quantification of triglycerides, induction of global cerebral ischemia followed by reperfusion was performed. Later, euthanasia, brains harvest and visceral fat weighing were performed. Histopathological evaluation of brain lesions, quantification of the number of viable and non-viable cells in the cerebral cortex and hippocampus, and of cells marked by the anti-pKR-ERK1/2 and p-AMPKα antibodies in the cerebral cortex were performed. Hypertriglyceridemia and a significant increase in the amount of visceral fat were observed in the group that received hypercaloric diet (p <0.05). Histopathological evaluations showed that the group that received hypercaloric diet and was treated with the extract had fewer brain lesions of ischemia and reperfusion. The extract did not influence the number of viable and nonviable cells in the cerebral cortex and hippocampus, but significantly reduced p-ERK1 / 2 and p-AMPKα cell labelling in the hypercaloric diet group (p <0.05). In conclusion, ethanolic extract of pequi peel reduces induced brain lesions in rats fed a hypercaloric diet and has a modulatory effect on the expression of ERK1 / 2 and AMPKα in the cerebral cortex. / O objetivo com esse estudo foi determinar o efeito do extrato etanólico da casca de pequi sobre dano cerebral induzido em ratas submetidas a dieta hipercalórica e as expressões das formas ativas da ERK1/2 e AMPKα no córtex cerebral. Utilizaram-se 48 ratas alocadas em dois grupos de 24, de acordo com a dieta utilizada, hipercalórica ou comercial, fornecidas diariamente por 60 dias. Os animais foram distribuídos em dois subgrupos de 12, tratados ou não com o extrato, administrado diariamente 30 dias após o início das dietas. Foi realizada quantificação dos triglicerídeos e indução de isquemia cerebral global seguida de reperfusão. Seguido à eutanásia, colheram-se os encéfalos e pesou-se a gordura visceral. Foram feitas avaliação histopatológica das lesões no encéfalo, quantificação do número de células viáveis e inviáveis no córtex cerebral e hipocampo e células marcadas pelos anticorpos anti p-ERK1/2 e p-AMPKα no córtex cerebral. Havia hipertrigliceridemia e aumento significativo na quantidade de gordura visceral no grupo que recebeu dieta hipercalórica (p < 0,05). O grupo que recebeu dieta hipercalórica e foi tratado com o extrato apresentou menos lesões cerebrais de isquemia e reperfusão. O extrato não influenciou o número de células viáveis e inviáveis no córtex cerebral e hipocampo, porém, reduziu significativamente a marcação pela pERK1/2 e p-AMPKα no grupo da dieta hipercalórica (p < 0,05). Concluiu-se que o extrato etanólico da casca de pequi reduz lesões cerebrais induzidas em ratas alimentadas com dieta hipercalórica e apresenta efeito modulatório sobre a expressão da ERK1/2 e da AMPKα no córtex cerebral.

No description available.

INTRODUÇÃO: O Acidente Vascular Cerebral Isquêmico (AVCI) é o evento mais freqüente dentre os AVCs, sendo caracterizado pela interrupção da irrigação sanguínea ao cérebro, a qual pode acarretar em lesão celular e alterações nas funções neurológicas. As manifestações clínicas desta doença podem incluir alterações das funções motoras, sensitivas, cognitivas, perceptivas, da linguagem entre outras. Sendo assim, é extremamente importante que sejam identificadas possíveis alterações nas vias auditivas, periférica e central, as quais podem prejudicar a qualidade de vida destes indivíduos. OBJETIVO: caracterizar os achados das avaliações comportamentais, eletroacústicas e eletrofisiológicas da audição em indivíduos destros com lesão isquêmica do hemisfério cerebral direito, bem como compará-los aos obtidos em indivíduos normais da mesma faixa etária. MÉTODOS: foram realizadas audiometria tonal, logoaudiometria, medidas de imitância acústica, potencial evocado auditivo de tronco encefálico (PEATE), potencial evocado auditivo de média latência (PEAML) e potencial cognitivo (P300) em 17 indivíduos com lesão do hemisfério direito (grupo pesquisa) e 25 normais (grupo controle), com idades entre 20 e 70 anos. RESULTADOS: Na análise dos dados qualitativos não foram encontradas alterações na avaliação comportamental da audição para os dois grupos. Ambos os grupos apresentaram alterações nos resultados do PEATE e do PEAML, sendo que houve diferença estatisticamente significante entre os grupos, para esses dois potenciais, nas quais o grupo pesquisa apresentou maior ocorrência de alterações. No PEATE a alteração mais freqüente foi do tipo tronco encefálico baixo, sendo que, entre os grupos, houve diferença estatisticamente significante, na qual o grupo pesquisa mostrou maior ocorrência dessa alteração. No PEAML a alteração predominante foi do tipo ambas (efeito orelha e efeito eletrodo ocorrendo concomitantemente) para o grupo pesquisa, e do tipo efeito eletrodo para o grupo controle. Na análise dos dados quantitativos (realizada apenas para os potenciais evocados auditivos) verificou-se, no PEATE, que ocorreu diferença estatisticamente significante entre os grupos com relação às latências das ondas III e V e interpicos I-III e I-V. Para o PEAML, a diferença estatisticamente significante entre os grupos ocorreu apenas para a latência da onda Na na posição C3/A1. Para o P300, ocorreu diferença entre os grupos com relação à latência da onda P300, sendo que o grupo pesquisa apresentou tempo médio de latência maior; além disso, houve uma tendência estatisticamente significante entre as orelhas direita e esquerda dentro do grupo pesquisa, mostrando aumento de latência da onda P300 na orelha direita. CONCLUSÃO: Indivíduos destros com lesão de hemisfério direito apresentaram limiares auditivos dentro da normalidade na avaliação comportamental da audição, entretanto, apresentaram resultados indicativos de déficit no sistema nervoso auditivo central, nas avaliações eletrofisiológicas da audição. Foram observados comprometimentos em tronco encefálico baixo, bem como nas regiões subcorticais e corticais. Dificuldades auditivas não foram percebidas pelos indivíduos, sugerindo que, provavelmente tal sinal possa estar relacionado à uma heminegligência auditiva. Tornam-se necessários mais estudos que avaliem a via auditiva central destes indivíduos para uma melhor caracterização dos achados eletrofisiológicos / INTRODUCTION: The ischemic cerebral stroke (ICS) is the most frequent event among cerebral strokes. It is characterized by the interruption of blood supply to the brain, which can lead to cell damage and alterations in neurological functions. The clinical manifestations of this disease may include alterations in motor, sensory, cognitive, perceptual and language functions among others. Therefore, the identification of possible alterations in both peripheral and central auditory pathways that may impair the quality of life of these individuals is extremely important. OBJECTIVE: To characterize the findings of behavioral, electrophysiological and electroacoustic hearing evaluations in right-handed individuals with right hemisphere ischemic lesion, and to compare such data to those obtained in normal individuals with the same age. METHODS: Pure tone audiometry, speech audiometry, acoustic immittance measures, brainstem auditory evoked potential (BAEP), Auditory Middle-Latency Response (AMLR) and cognitive potential (P300) were carried out in 17 subjects with right hemisphere lesions (research group) and 25 normal individuals (control group), aged between 20 and 70 years. RESULTS: No alterations were found on the qualitative data analysis of the hearing behavioral assessment of both groups. Both groups showed alterations in the BAEP and AMLR results, with statistically significant differences between groups for both potentials and a higher occurrence of alterations in the research group. The lower brainstem was the most frequent alteration type in the BAEP, and a statistically significant difference between groups was observed, with higher occurrence of such alteration in the research group. With regards the AMLR, the alteration predominantly observed was the Both type one (ear effect and electrode effect occurring concurrently) for the research group, and the electrode effect type one for the control group. In the analysis of quantitative data (performed only for the auditory evoked potentials), a statistically significant difference between groups was observed with respect to the BAEP latencies of waves III, V and interpeaks I-III and I-V. Regarding the AMLR measures, a statistically significant difference between groups was observed only for the Na wave latency in the C3/A1 position. For the P300, a difference between groups was observed, with higher mean latencies for the research group. In addition, there was a trend to statistically significant difference between right and left ears in the research group, which showed increased latency of P300 wave in the right ear. CONCLUSION: Right-handed individuals with right hemisphere lesion showed hearing thresholds within normal limits in the behavioral hearing assessment. However, they presented results indicative of central auditory nervous system deficits on the electrophysiological assessment of hearing. Alterations were observed in lower brainstem and in sub-cortical and cortical regions. Hearing difficulties were not perceived by these individuals, suggesting that this signal can probably be related to an auditory hemineglect. Further studies that evaluate the central auditory pathway of individuals with ICS are needed to better characterize the electrophysiological findings

Dissertation (Ph.D.)--University of South Florida, 2007. / Includes vita. Includes bibliographical references. Also available online.

Diss. (sammanfattning) Umeå : Umeå universitet, 2010.